Send to

Choose Destination
Am J Kidney Dis. 2019 Jul 11. pii: S0272-6386(19)30766-8. doi: 10.1053/j.ajkd.2019.03.433. [Epub ahead of print]

Kidney Complications of Immune Checkpoint Inhibitors: A Review.

Author information

Memorial Sloan Kettering Cancer Center; Weill Medical College of Cornell University, New York, NY.
Memorial Sloan Kettering Cancer Center; Weill Medical College of Cornell University, New York, NY. Electronic address:


Immunologic control of malignancy has long been recognized as an important determinant of disease progression. Recent advances in immunology have led to the focus on several mechanisms that can be targeted to achieve tumor suppression. In particular, checkpoint inhibition has evolved in less than a decade to become one of the most important strategies in cancer therapy, with a meaningful improvement in patient survival. Six agents have been approved for clinical use to date and many more are in the industry pipeline. The spectrum of malignancies responsive to immunotherapy ranges from advanced melanoma, for which the first immune checkpoint inhibitor ipilimumab was approved, to Hodgkin lymphoma, non-small cell lung cancer, renal cell carcinoma, and others. Notwithstanding its clinical benefits, checkpoint inhibition carries a risk for significant off-target toxicity stemming from the immune system activation. In this review, we discuss general principles of checkpoint inhibition, mechanisms of toxicity, and kidney complications of the treatment and propose diagnostic and treatment strategies when kidney injury occurs.


Acute kidney injury (AKI); cancer immunotherapy; checkpoint inhibitor; corticosteroids; cytotoxic T-lymphocyte associated protein 4 inhibitor; immune-related adverse effect (irAE); immunotherapy; interstitial nephritis; onconephrology; programmed cell death protein 1 inhibitor; renal function; review


Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center